Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future

Related Experiment Video

Updated: Jun 10, 2026

Preparation of Zinc Oxide Nanoparticles and the Evaluation of their Antibacterial Effects
06:42

Preparation of Zinc Oxide Nanoparticles and the Evaluation of their Antibacterial Effects

Published on: September 27, 2024

Tobias Welte1, Mathias W Pletz

  • 1Department of Pulmonary Medicine, Hannover Medical School, Hannover, Germany. welte.tobias@mh-hannover.de

International Journal of Antimicrobial Agents
|August 21, 2010
PubMed

Insights

Meticillin-resistant Staphylococcus aureus (MRSA) pneumonia requires effective antimicrobial therapy. This review discusses current and emerging treatments, highlighting the need for agents with lung penetration and low resistance potential.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Meticillin-resistant Staphylococcus aureus (MRSA) is a significant cause of hospital-acquired pneumonia.
  • Antimicrobial resistance complicates MRSA pneumonia treatment, leading to increased mortality.
  • Current guidelines recommend vancomycin and linezolid, with regional variations.

Purpose of the Study:

  • To review current and investigational antimicrobial agents for MRSA pneumonia.
  • To discuss criteria for effective MRSA pneumonia treatments, including antimicrobial activity, lung penetration, resistance, and safety.
  • To evaluate the efficacy of existing and novel therapies.

Main Methods:

  • Literature review of current and emerging antimicrobial agents for MRSA pneumonia.
  • Analysis of data from randomized controlled trials and approved indications.
  • Assessment of antimicrobial properties relevant to lung infections.

Main Results:

  • Vancomycin and linezolid are primary treatments, but some agents like tigecycline and daptomycin lack proven efficacy for pneumonia.
  • Newer agents including lipoglycopeptides (telavancin, dalbavancin, oritavancin), cephalosporins (ceftobiprole, ceftaroline), and iclaprim are under investigation.
  • Many potential agents lack robust randomized controlled trial data for MRSA pneumonia.

Conclusions:

  • Effective MRSA pneumonia treatment necessitates agents with specific activity, lung penetration, and favorable resistance profiles.
  • Ongoing research and development are crucial for expanding treatment options.
  • Further clinical trials are needed to establish the efficacy and safety of novel agents.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...